XOMA is a late-stage biotechnology company with a diverse portfolio of innovative therapeutic antibodies. The Company has built an expertise in allosteric modulation and has applied that expertise to expand the therapeutic potential of monoclonal antibodies. The first compound from XOMA's allosteric modulating antibody program is gevokizumab, an IL-1 beta modulating antibody. XOMA has partnered with SERVIER, a global pharmaceutical company based in France, to develop and commercialize gevokizumab for the global market, and the companies are conducting a global Phase 3 program in people with Behçet's disease uveitis and non-infectious uveitis.
Each company also has a proof-of-concept (POC) clinical program in place to identify other IL-1 mediated diseases that could be treated with gevokizumab. One of these POC studies led XOMA to select its next Phase 3 indication, pyoderma gangrenosum, a rare ulcerative skin disease.
XOMA's scientific research also produced the XMet program, which consists of three classes of preclinical allosteric modulating antibodies, including Selective Insulin Receptor Modulators (SIRMs) that could have a major impact on the treatment of diabetes. XOMA will retain the compound that has potential to treat several rare insulin dysfunction-related diseases and to out-license the compounds that could address the diabetes markets.
Today, XOMA's principal activities are aligned with the Company's corporate goal of becoming a commercial organization selling products to the U.S.-based specialist prescriber. These include:
XOMA's antibody technology platforms include an unmatched collection of antibody phage display libraries and proprietary Human Engineering™, Bacterial Cell Expression (BCE), affinity maturation and manufacturing technologies. BCE is a key breakthrough biotechnology for the discovery and manufacturing of antibodies and other proteins. Overall, 60 pharmaceutical and biotechnology companies have signed BCE licenses, and several licensed product candidates are currently in clinical development. XOMA is entitled to development-related milestones and royalties on antibodies covered under these licenses.
XOMA is located in Berkeley, California.
May 7, 2015 at 4:30 PM ET
First Quarter 2015 Financial Results Conference Call
May 6, 2015 at 8:35 AM ET
Credit Suisse Antibody Day 2015